RxDoctor Payments Data

Andrea Gordon

Nurse Practitioner · Kenosha, WINPI 1306377023

Payments from drug & device makers

$2,520in general payments, 2019–2025

Across 111 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$585
  • Gilead$526
  • Johnson & Johnson$412
  • Takeda Pharmaceuticals U.S.A., Inc.$232
  • Ardelyx, Inc.$138
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$107
  • plus $521 from 15 others

What the payments were for

  • Food & beverage$2,31792%
  • Education$2038%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,520 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$24,045
Medicare patients
234
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide57$44,422
SutabSod Sulf/Pot Chloride/Mag Sulf33$5,398
Omeprazole346$4,483
Pantoprazole Sodium248$3,428
CholestyramineCholestyramine (With Sugar)24$1,947
Colestipol Hcl12$1,384
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl79$1,054
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$1,049
Sucralfate14$1,012
Famotidine55$929
Dicyclomine Hcl27$580
Esomeprazole Magnesium17$579
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl20$316
Ondansetron Hcl30$169
Metoclopramide Hcl182$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$585$44,42257 claims
Braintree Laboratories, Inc.Sutab$60$5,39833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →